Description

Semaglutide is categorized as a glucagon-like peptide-1 receptor agonist (GLP-1 RAs). These compounds mimic the GLP-1 hormone that is typically released in the gut in response to food intake. When GLP-1 serum levels increase, secretion of insulin increases as well and reduces glucose levels in the body. That being said, research from the past 15 years shows that semaglutide has been successful in treating Type 2 diabetes. Additionally, increased levels of GLP-1 communicates with the brain area that suppresses appetite and signals the feeling of fullness. Extensive research has been conducted studying the mechanism through which administration of the peptide can potentially lead to significant weight loss.